{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T18:35:14Z","timestamp":1789670114002,"version":"4.0.1"},"reference-count":193,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,9,8]],"date-time":"2023-09-08T00:00:00Z","timestamp":1694131200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:p>Cardio-oncology is an emerging field that seeks to enhance quality of life and longevity of cancer survivors. It is pertinent for clinicians to understand the cellular mechanisms of prescribed therapies, as this contributes to robust understanding of complex treatments and off-target effects, improved communication with patients, and guides long term care with the goal to minimise or prevent cardiovascular complications. Our aim is to review the cellular mechanisms of cardiotoxicity involved in commonly used anti-cancer treatments and identify gaps in literature and strategies to mitigate cardiotoxicity effects and guide future research endeavours.<\/jats:p>","DOI":"10.3389\/fcvm.2023.1150569","type":"journal-article","created":{"date-parts":[[2023,9,8]],"date-time":"2023-09-08T13:48:21Z","timestamp":1694180901000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":12,"title":["Cardiotoxicity of anti-cancer drugs: cellular mechanisms and clinical implications"],"prefix":"10.3389","volume":"10","author":[{"given":"Cecilia","family":"Kwok","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Nolan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,9,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"409","DOI":"10.3322\/caac.21731","article-title":"Cancer treatment and survivorship statistics, 2022","volume":"1","author":"Miller","year":"2022","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/S0140-6736(17)33326-3","article-title":"Global surveillance of trends in cancer survival 2000\u201314 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries","volume":"391","author":"Allemani","year":"2018","journal-title":"Lancet"},{"key":"B3","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1038\/bjc.2015.265","article-title":"Is England closing the international gap in cancer survival?","volume":"113","author":"Walters","year":"2015","journal-title":"Br J Cancer"},{"key":"B4","year":"2021"},{"key":"B5","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/j.jacbts.2016.05.008","article-title":"21st century cardio-oncology: identifying cardiac safety signals in the era of personalized medicine","volume":"1","author":"Sheng","year":"2016","journal-title":"JACC Basic Transl Sci"},{"key":"B6","doi-asserted-by":"publisher","first-page":"4229","DOI":"10.1093\/eurheartj\/ehad196","article-title":"2022 ESC guidelines on cardio-oncology developed in collaboration with the European hematology association (EHA), the European society for therapeutic radiology and oncology (ESTRO) and the international cardio-oncology society (IC-OS): developed by the task force on cardio-oncology of the European society of cardiology (ESC)","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur Heart J"},{"key":"B7","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/S0140-6736(18)30199-5","article-title":"Should basic science matter to clinicians?","volume":"391","author":"Filewod","year":"2018","journal-title":"Lancet"},{"key":"B8","doi-asserted-by":"publisher","first-page":"2070","DOI":"10.1212\/WNL.0b013e318294b48a","article-title":"Why our patients (and we) need basic science research","volume":"80","author":"Schor","year":"2013","journal-title":"Neurology"},{"key":"B9","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/j.jcmg.2012.11.017","article-title":"Low to moderate dose anthracycline-based chemotherapy is associated with early noninvasive imaging evidence of subclinical cardiovascular disease","volume":"6","author":"Drafts","year":"2013","journal-title":"JACC Cardiovasc Imaging"},{"key":"B10","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1007\/s12012-007-0015-3","article-title":"Role of anthracyclines in the era of targeted therapy","volume":"7","author":"Cort\u00e9s-Funes","year":"2007","journal-title":"Cardiovasc Toxicol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1200\/JCO.2011.40.1273","article-title":"Decline in the use of anthracyclines for breast cancer","volume":"30","author":"Giordano","year":"2012","journal-title":"J Clin Oncol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1016\/j.hrthm.2019.04.008","article-title":"Ibrutinib promotes atrial fibrillation by inducing structural remodeling and calcium dysregulation in the atrium","volume":"16","author":"Jiang","year":"2019","journal-title":"Heart Rhythm"},{"key":"B13","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1172\/JCI72931","article-title":"Cardiotoxicity of doxorubicin is mediated through mitochondrial iron accumulation","volume":"124","author":"Ichikawa","year":"2014","journal-title":"J Clin Invest"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1038\/nm.2919","article-title":"Identification of the molecular basis of doxorubicin-induced cardiotoxicity","volume":"18","author":"Zhang","year":"2012","journal-title":"Nat Med"},{"key":"B15","first-page":"460","article-title":"Effect of anthracycline antibiotics on oxygen radical formation in rat heart","volume":"43","author":"Doroshow","year":"1983","journal-title":"Cancer Res"},{"key":"B16","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.taap.2018.07.020","article-title":"RNA sequence analysis of inducible pluripotent stem cell-derived cardiomyocytes reveals altered expression of DNA damage and cell cycle genes in response to doxorubicin","volume":"356","author":"Reyes","year":"2018","journal-title":"Toxicol Appl Pharmacol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"8717","DOI":"10.1038\/srep08717","article-title":"Anthracycline-containing chemotherapy causes long-term impairment of mitochondrial respiration and increased reactive oxygen species release in skeletal muscle","volume":"5","author":"Gouspillou","year":"2015","journal-title":"Sci Rep"},{"key":"B18","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1007\/s12012-007-0009-1","article-title":"Role of mtDNA lesions in anthracycline cardiotoxicity","volume":"7","author":"Lebrecht","year":"2007","journal-title":"Cardiovasc Toxicol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-016-0028-x","article-title":"Doxorubicin induces cardiotoxicity through upregulation of death receptors mediated apoptosis in cardiomyocytes","volume":"7","author":"Zhao","year":"2017","journal-title":"Sci Rep"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41419-021-03614-x","article-title":"Regulated cell death pathways in doxorubicin-induced cardiotoxicity","volume":"12","author":"Christidi","year":"2021","journal-title":"Cell Death Dis"},{"key":"B21","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1038\/nrm831","article-title":"Cellular roles of DNA topoisomerases: a molecular perspective","volume":"3","author":"Wang","year":"2002","journal-title":"Nat Rev Mol Cell Biol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/B978-0-12-397833-2.00013-3","article-title":"Doxorubicin cardiotoxicity revisited: ROS versus Top2","volume":"2012","author":"Lyu","year":"2012","journal-title":"Recent Adv Cancer Res Therapy"},{"key":"B23","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1161\/CIRCULATIONAHA.108.799700","article-title":"Acute doxorubicin cardiotoxicity is associated with p53-induced inhibition of the mammalian target of rapamycin pathway","volume":"119","author":"Zhu","year":"2009","journal-title":"Circulation"},{"key":"B24","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1161\/CIRCRESAHA.119.314681","article-title":"Mitochondrial determinants of doxorubicin-induced cardiomyopathy","volume":"126","author":"Wallace","year":"2020","journal-title":"Circ Res"},{"key":"B25","doi-asserted-by":"publisher","first-page":"8839","DOI":"10.1158\/0008-5472.CAN-07-1649","article-title":"Topoisomerase II\u03b2\u2013mediated DNA double-strand breaks: implications in doxorubicin cardiotoxicity and prevention by dexrazoxane","volume":"67","author":"Lyu","year":"2007","journal-title":"Cancer Res"},{"key":"B26","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s11010-005-5905-8","article-title":"Targeted disruption of p53 attenuates doxorubicin-induced cardiac toxicity in mice","volume":"273","author":"Shizukuda","year":"2005","journal-title":"Mol Cell Biochem"},{"key":"B27","doi-asserted-by":"publisher","first-page":"9287","DOI":"10.1158\/0008-5472.CAN-10-2664","article-title":"Nox2 NADPH oxidase promotes pathologic cardiac remodeling associated with doxorubicin chemotherapy","volume":"70","author":"Zhao","year":"2010","journal-title":"Cancer Res"},{"key":"B28","doi-asserted-by":"publisher","first-page":"349","DOI":"10.3390\/antiox10030349","article-title":"Nrf2 signaling pathway in chemoprotection and doxorubicin resistance: potential application in drug discovery","volume":"10","author":"Mirzaei","year":"2021","journal-title":"Antioxidants"},{"key":"B29","doi-asserted-by":"publisher","first-page":"101394","DOI":"10.1016\/j.redox.2019.101394","article-title":"Teaching the basics of the mechanism of doxorubicin-induced cardiotoxicity: have we been barking up the wrong tree?","volume":"29","author":"Kalyanaraman","year":"2020","journal-title":"Redox Biol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"189","DOI":"10.20455\/ros.2016.835","article-title":"Doxorubicin redox biology: redox cycling, topoisomerase inhibition, and oxidative stress","volume":"1","author":"Zhu","year":"2016","journal-title":"React Oxyg Spec (Apex, NC)"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1016\/j.bpj.2008.10.042","article-title":"Doxorubicin inactivates myocardial cytochrome c oxidase in rats: cardioprotection by mito-Q","volume":"96","author":"Chandran","year":"2009","journal-title":"Biophys J"},{"key":"B32","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1007\/s00395-006-0609-0","article-title":"Reduced repolarization reserve due to anthracycline therapy facilitates torsade de pointes induced by I Kr blockers","volume":"102","author":"Milberg","year":"2007","journal-title":"Basic Res Cardiol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1080\/10715760000300201","article-title":"Mitochondria, oxidative stress and aging","volume":"32","author":"Sastre","year":"2000","journal-title":"Free Radical Res"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1918","DOI":"10.1016\/j.yexcr.2008.01.011","article-title":"Free radicals and senescence","volume":"314","author":"Lu","year":"2008","journal-title":"Exp Cell Res"},{"key":"B35","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1016\/j.lfs.2013.10.013","article-title":"The role of autophagy in doxorubicin-induced cardiotoxicity","volume":"93","author":"Dirks-Naylor","year":"2013","journal-title":"Life Sci"},{"key":"B36","doi-asserted-by":"publisher","first-page":"166525","DOI":"10.1016\/j.bbadis.2022.166525","article-title":"Resolvin E1 attenuates doxorubicin-induced cardiac fibroblast senescence: a key role for IL-1\u03b2","volume":"1868","author":"Espitia-Corredor","year":"2022","journal-title":"Biochim Biophys Acta-Mol Basis Dis"},{"key":"B37","doi-asserted-by":"publisher","first-page":"e0221940","DOI":"10.1371\/journal.pone.0221940","article-title":"Doxorubicin induces trans-differentiation and MMP1 expression in cardiac fibroblasts via cell death-independent pathways","volume":"14","author":"Narikawa","year":"2019","journal-title":"PLoS One"},{"key":"B38","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1111\/j.1474-9726.2007.00358.x","article-title":"Induction of premature senescence in cardiomyocytes by doxorubicin as a novel mechanism of myocardial damage","volume":"7","author":"Maejima","year":"2008","journal-title":"Aging Cell"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1058435","DOI":"10.3389\/fragi.2022.1058435","article-title":"Anthracycline-induced cardiotoxicity and senescence","volume":"3","author":"Booth","year":"2022","journal-title":"Front Aging"},{"key":"B40","first-page":"12216","article-title":"Effects of PPAR\u03b1\/PGC-1\u03b1 on the energy metabolism remodeling and apoptosis in the doxorubicin induced mice cardiomyocytes in vitro","volume":"8","author":"Yang","year":"2015","journal-title":"Int J Clin Exp Pathol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"e12733","DOI":"10.1371\/journal.pone.0012733","article-title":"Doxorubicin in vivo rapidly alters expression and translation of myocardial electron transport chain genes, leads to ATP loss and caspase 3 activation","volume":"5","author":"Pointon","year":"2010","journal-title":"PLoS One"},{"key":"B42","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s12964-023-01077-5","article-title":"Role of oxidative stress and inflammation-related signaling pathways in doxorubicin-induced cardiomyopathy","volume":"21","author":"Shi","year":"2023","journal-title":"Cell Commun Signal"},{"key":"B43","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.bbrc.2019.12.027","article-title":"Dexrazoxane ameliorates doxorubicin-induced cardiotoxicity by inhibiting both apoptosis and necroptosis in cardiomyocytes","volume":"523","author":"Yu","year":"2020","journal-title":"Biochem Biophys Res Commun"},{"key":"B44","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.yjmcc.2019.08.009","article-title":"Doxorubicin induces cardiomyocyte pyroptosis via the TINCR-mediated posttranscriptional stabilization of NLR family pyrin domain containing 3","volume":"136","author":"Meng","year":"2019","journal-title":"J Mol Cell Cardiol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.critrevonc.2005.01.005","article-title":"Predicting drug response and toxicity based on gene polymorphisms","volume":"54","author":"Robert","year":"2005","journal-title":"Crit Rev Oncol Hematol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"3267","DOI":"10.2174\/092986709788803312","article-title":"Doxorubicin: the good, the bad and the ugly effect","volume":"16","author":"Carvalho","year":"2009","journal-title":"Curr Med Chem"},{"key":"B47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40959-019-0056-3","article-title":"Detection of subclinical cardiotoxicity in sarcoma patients receiving continuous doxorubicin infusion or pre-treatment with dexrazoxane before bolus doxorubicin","volume":"6","author":"Li","year":"2020","journal-title":"Cardio-Oncology"},{"key":"B48","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.tox.2008.10.011","article-title":"Evaluation of the topoisomerase II-inactive bisdioxopiperazine ICRF-161 as a protectant against doxorubicin-induced cardiomyopathy","volume":"255","author":"Martin","year":"2009","journal-title":"Toxicology"},{"key":"B49","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1016\/j.freeradbiomed.2003.08.005","article-title":"The oral iron chelator ICL670A (deferasirox) does not protect myocytes against doxorubicin","volume":"35","author":"Hasinoff","year":"2003","journal-title":"Free Radic Biol Med"},{"key":"B50","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1111\/j.1745-7254.2006.00409.x","article-title":"Deferiprone protects the isolated atria from cardiotoxicity induced by doxorubicin","volume":"27","author":"Lj","year":"2006","journal-title":"Acta Pharmacol Sin"},{"key":"B51","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/BF00686629","article-title":"Comparison of the protective effects of desferrioxamine and ICRF-187 against doxorubicin-induced toxicity in spontaneously hypertensive rats","volume":"35","author":"Herman","year":"1994","journal-title":"Cancer Chemother Pharmacol"},{"key":"B52","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2407-14-1","article-title":"Dexrazoxane may prevent doxorubicin-induced DNA damage via depleting both topoisomerase II isoforms","volume":"14","author":"Deng","year":"2014","journal-title":"BMC Cancer"},{"key":"B53","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1007\/s11912-001-0016-5","article-title":"Liposomal encapsulated anthracyclines: new therapeutic horizons","volume":"3","author":"Muggia","year":"2001","journal-title":"Curr Oncol Rep"},{"key":"B54","doi-asserted-by":"publisher","first-page":"3421","DOI":"10.1158\/0008-5472.CAN-07-5836","article-title":"ABT-263: a potent and orally bioavailable bcl-2 family inhibitor","volume":"68","author":"Tse","year":"2008","journal-title":"Cancer Res"},{"key":"B55","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1023\/A:1011195320446","article-title":"The basic biology of HER2","volume":"12","author":"Rubin","year":"2001","journal-title":"Ann Oncol"},{"key":"B56","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","article-title":"Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial","volume":"376","author":"Bang","year":"2010","journal-title":"Lancet"},{"key":"B57","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1056\/NEJM200103153441101","article-title":"Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2","volume":"344","author":"Slamon","year":"2001","journal-title":"N Engl J Med"},{"key":"B58","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1200\/JCO.2014.56.9590","article-title":"Lapatinib or trastuzumab plus taxane therapy for human epidermal growth factor receptor 2-positive advanced breast cancer: final results of NCIC CTG MA","volume":"33","author":"Gelmon","year":"2015","journal-title":"J Clin Oncol"},{"key":"B59","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1158\/0008-5472.CAN-08-3389","article-title":"Basal subtype and MAPK\/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition","volume":"69","author":"Mirzoeva","year":"2009","journal-title":"Cancer Res"},{"key":"B60","doi-asserted-by":"publisher","first-page":"45186","DOI":"10.18632\/oncotarget.9870","article-title":"HER2 reduces breast cancer radiosensitivity by activating focal adhesion kinase in vitro and in vivo","volume":"7","author":"Hou","year":"2016","journal-title":"Oncotarget"},{"key":"B61","first-page":"4892","article-title":"Down-regulation of the erbB-2 receptor by trastuzumab (herceptin) enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in breast and ovarian cancer cell lines that overexpress erbB-2","volume":"61","author":"Cuello","year":"2001","journal-title":"Cancer Res"},{"key":"B62","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1038\/s41416-018-0318-0","article-title":"Early immune modulation by single-agent trastuzumab as a marker of trastuzumab benefit","volume":"119","author":"Triulzi","year":"2018","journal-title":"Br J Cancer"},{"key":"B63","doi-asserted-by":"publisher","first-page":"5374","DOI":"10.1158\/0008-5472.CAN-16-2774","article-title":"Trastuzumab increases HER2 uptake and cross-presentation by dendritic cells","volume":"77","author":"Gall","year":"2017","journal-title":"Cancer Res"},{"key":"B64","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1172\/JCI61226","article-title":"Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer","volume":"122","author":"Kohrt","year":"2012","journal-title":"J Clin Invest"},{"key":"B65","doi-asserted-by":"publisher","first-page":"4379","DOI":"10.4049\/jimmunol.1402891","article-title":"Trastuzumab triggers phagocytic killing of high HER2 cancer cells in vitro and in vivo by interaction with fc\u03b3 receptors on macrophages","volume":"194","author":"Shi","year":"2015","journal-title":"J Immunol"},{"key":"B66","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1038\/nm0502-459","article-title":"Erbb2 is essential in the prevention of dilated cardiomyopathy","volume":"8","author":"Crone","year":"2002","journal-title":"Nat Med"},{"key":"B67","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/j.yexcr.2008.08.015","article-title":"The role of neuregulin-1\u03b2\/ErbB signaling in the heart","volume":"315","author":"Pentassuglia","year":"2009","journal-title":"Exp Cell Res"},{"key":"B68","doi-asserted-by":"publisher","first-page":"346","DOI":"10.3390\/biology10040346","article-title":"ERK1\/2: an integrator of signals that alters cardiac homeostasis and growth","volume":"10","author":"Gilbert","year":"2021","journal-title":"Biology (Basel)"},{"key":"B69","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.canlet.2009.07.005","article-title":"Focal adhesion kinase: a prominent determinant in breast cancer initiation, progression and metastasis","volume":"289","author":"Luo","year":"2010","journal-title":"Cancer Lett"},{"key":"B70","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1159\/000493037","article-title":"PI3K\u2013AKT pathway protects cardiomyocytes against hypoxia-induced apoptosis by MitoKATP-mediated mitochondrial translocation of pAKT","volume":"49","author":"Song","year":"2018","journal-title":"Cell Physiol Biochem"},{"key":"B71","first-page":"1005","article-title":"Implications of autophagy and oxidative stress in trastuzumab-mediated cardiac toxicities","volume":"2","author":"Mohan","year":"2017","journal-title":"Austin Pharmacol Pharm"},{"key":"B72","doi-asserted-by":"publisher","first-page":"e79543","DOI":"10.1371\/journal.pone.0079543","article-title":"Trastuzumab alters the expression of genes essential for cardiac function and induces ultrastructural changes of cardiomyocytes in mice","volume":"8","author":"ElZarrad","year":"2013","journal-title":"PLoS One"},{"key":"B73","doi-asserted-by":"publisher","first-page":"2080","DOI":"10.1074\/jbc.M804570200","article-title":"Blockade of the erbB2 receptor induces cardiomyocyte death through mitochondrial and reactive oxygen species-dependent pathways","volume":"284","author":"Gordon","year":"2009","journal-title":"J Biol Chem"},{"key":"B74","doi-asserted-by":"publisher","first-page":"2128","DOI":"10.1172\/JCI23073","article-title":"PI3K rescues the detrimental effects of chronic Akt activation in the heart during ischemia\/reperfusion injury","volume":"115","author":"Nagoshi","year":"2005","journal-title":"J Clin Invest"},{"key":"B75","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1038\/nrm1983","article-title":"Regulation of cardiac hypertrophy by intracellular signalling pathways","volume":"7","author":"Heineke","year":"2006","journal-title":"Nat Rev Mol Cell Biol"},{"key":"B76","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.tem.2013.11.004","article-title":"Cardiomyocyte health: adapting to metabolic changes through autophagy","volume":"25","author":"Kubli","year":"2014","journal-title":"Trends Endocrinol Metab"},{"key":"B77","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1093\/abt\/tby003","article-title":"Trastuzumab-mediated cardiotoxicity: current understanding, challenges, and frontiers","volume":"1","author":"Mohan","year":"2018","journal-title":"Antib Therapeutics"},{"key":"B78","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1158\/1535-7163.MCT-15-0741","article-title":"Trastuzumab, but not pertuzumab, dysregulates HER2 signaling to mediate inhibition of autophagy and increase in reactive oxygen species production in human cardiomyocytes","volume":"15","author":"Mohan","year":"2016","journal-title":"Mol Cancer Ther"},{"key":"B79","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00395-013-0360-2","article-title":"Novel aspects of excitation\u2013contraction coupling in heart failure","volume":"108","author":"Neef","year":"2013","journal-title":"Basic Res Cardiol"},{"key":"B80","doi-asserted-by":"publisher","first-page":"24857","DOI":"10.1074\/jbc.M109.003186","article-title":"Critical role of nuclear calcium\/calmodulin-dependent protein kinase II\u03b4B in cardiomyocyte survival in cardiomyopathy","volume":"284","author":"Little","year":"2009","journal-title":"J Biol Chem"},{"key":"B81","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.yjmcc.2017.12.015","article-title":"Improvement of cardiomyocyte function by a novel pyrimidine-based CaMKII-inhibitor","volume":"115","author":"Neef","year":"2018","journal-title":"J Mol Cell Cardiol"},{"key":"B82","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1210\/rp.59.1.141","article-title":"Cardiomyocyte calcium and calcium\/calmodulin-dependent protein kinase II: friends or foes?","volume":"59","author":"Zhang","year":"2004","journal-title":"Recent Prog Horm Res"},{"key":"B83","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1161\/01.RES.0000258172.74570.e6","article-title":"\u03b2-Adrenergic enhancement of sarcoplasmic reticulum calcium leak in cardiac myocytes is mediated by calcium\/calmodulin-dependent protein kinase","volume":"100","author":"Curran","year":"2007","journal-title":"Circ Res"},{"key":"B84","doi-asserted-by":"publisher","first-page":"2425","DOI":"10.1056\/NEJMoa1509388","article-title":"Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia","volume":"373","author":"Burger","year":"2015","journal-title":"N Engl J Med"},{"key":"B85","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1097\/PPO.0000000000000412","article-title":"BTK inhibitors: present and future","volume":"25","author":"Burger","year":"2019","journal-title":"Cancer J (Sudbury, Mass)"},{"key":"B86","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12943-018-0779-z","article-title":"Role of bruton\u2019s tyrosine kinase in B cells and malignancies","volume":"17","author":"Pal Singh","year":"2018","journal-title":"Mol Cancer"},{"key":"B87","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.amjcard.2019.05.029","article-title":"Rates and risk of atrial arrhythmias in patients treated with ibrutinib compared with cytotoxic chemotherapy","volume":"124","author":"Fradley","year":"2019","journal-title":"Am J Cardiol"},{"key":"B88","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.3324\/haematol.2017.171041","article-title":"Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials","volume":"102","author":"Brown","year":"2017","journal-title":"Haematologica"},{"key":"B89","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13045-018-0626-0","article-title":"Predictors of atrial fibrillation in ibrutinib-treated CLL patients: a prospective study","volume":"11","author":"Reda","year":"2018","journal-title":"J Hematol Oncol"},{"key":"B90","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1182\/bloodadvances.2017009720","article-title":"Cumulative incidence, risk factors, and management of atrial fibrillation in patients receiving ibrutinib","volume":"1","author":"Wiczer","year":"2017","journal-title":"Blood Advances"},{"key":"B91","doi-asserted-by":"publisher","first-page":"e2701","DOI":"10.7759\/cureus.2701","article-title":"Management of atrial fibrillation in patients on ibrutinib: a Cleveland clinic experience","volume":"10","author":"Khalid","year":"2018","journal-title":"Cureus"},{"key":"B92","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1111\/jth.13651","article-title":"Ibrutinib-associated bleeding: pathogenesis, management and risk reduction strategies","volume":"15","author":"Shatzel","year":"2017","journal-title":"J Thromb Haemostasis"},{"key":"B93","doi-asserted-by":"publisher","first-page":"792310","DOI":"10.3389\/fcvm.2021.792310","article-title":"Arrhythmia patterns in patients on ibrutinib","volume":"8","author":"Fazal","year":"2021","journal-title":"Front Cardiovasc Med"},{"key":"B94","doi-asserted-by":"publisher","first-page":"e0211228","DOI":"10.1371\/journal.pone.0211228","article-title":"Ibrutinib increases the risk of hypertension and atrial fibrillation: systematic review and meta-analysis","volume":"14","author":"Caldeira","year":"2019","journal-title":"PLoS One"},{"key":"B95","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1182\/blood.2019000840","article-title":"Hypertension and incident cardiovascular events following ibrutinib initiation","volume":"134","author":"Dickerson","year":"2019","journal-title":"Blood"},{"key":"B96","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1016\/j.jacc.2019.07.056","article-title":"Cardiovascular toxicities associated with ibrutinib","volume":"74","author":"Salem","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"B97","first-page":"ytx006","article-title":"Association between ibrutinib and mid-cavitary takotsubo cardiomyopathy: a case report and a review of chemotherapy-induced takostubo\u2019s cardiomyopathy","volume":"1","author":"Giza","year":"2017","journal-title":"Eur Heart J Case Rep"},{"key":"B98","doi-asserted-by":"publisher","first-page":"416","DOI":"10.3389\/fphys.2013.00416","article-title":"Src as the link between inflammation and cancer","volume":"4","author":"Liu","year":"2014","journal-title":"Front Physiol"},{"key":"B99","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1161\/CIRCULATIONAHA.120.049210","article-title":"Ibrutinib-mediated atrial fibrillation attributable to inhibition of C-terminal Src kinase","volume":"142","author":"Xiao","year":"2020","journal-title":"Circulation"},{"key":"B100","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1056\/NEJMoa1509981","article-title":"Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia","volume":"374","author":"Byrd","year":"2016","journal-title":"N Engl J Med"},{"key":"B101","doi-asserted-by":"publisher","first-page":"2530","DOI":"10.1161\/CIRCULATIONAHA.118.034621","article-title":"Inflammation and NLRP3 inflammasome activation initiated in response to pressure overload by Ca2+\/calmodulin-dependent protein kinase II \u03b4 signaling in cardiomyocytes are essential for adverse cardiac remodeling","volume":"138","author":"Suetomi","year":"2018","journal-title":"Circulation"},{"key":"B102","doi-asserted-by":"publisher","first-page":"2227","DOI":"10.1161\/CIRCULATIONAHA.118.035202","article-title":"Enhanced cardiomyocyte NLRP3 inflammasome signaling promotes atrial fibrillation","volume":"138","author":"Yao","year":"2018","journal-title":"Circulation"},{"key":"B103","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1161\/CIRCULATIONAHA.120.052047","article-title":"Cardio-oncology: a win-win situation: how solving the mystery of an ibrutinib off-target effect reveals new insights into atrial fibrillation mechanisms","volume":"142","author":"Awan","year":"2020","journal-title":"Am Heart Assoc"},{"key":"B104","doi-asserted-by":"publisher","first-page":"3829","DOI":"10.1182\/blood-2014-10-604272","article-title":"Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling","volume":"124","author":"McMullen","year":"2014","journal-title":"Blood"},{"key":"B105","doi-asserted-by":"publisher","first-page":"998","DOI":"10.2353\/ajpath.2009.090126","article-title":"Reduced phosphoinositide 3-kinase (p110\u03b1) activation increases the susceptibility to atrial fibrillation","volume":"175","author":"Pretorius","year":"2009","journal-title":"Am J Pathol"},{"key":"B106","doi-asserted-by":"publisher","first-page":"101432","DOI":"10.1016\/j.redox.2020.101432","article-title":"Enhanced cardiomyocyte reactive oxygen species signaling promotes ibrutinib-induced atrial fibrillation","volume":"30","author":"Yang","year":"2020","journal-title":"Redox Biol"},{"key":"B107","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1111\/sji.12333","article-title":"Targets for ibrutinib beyond B cell malignancies","volume":"82","author":"Bergl\u00f6f","year":"2015","journal-title":"Scand J Immunol"},{"key":"B108","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1038\/s41375-021-01123-6","article-title":"BTK gatekeeper residue variation combined with cysteine 481 substitution causes super-resistance to irreversible inhibitors acalabrutinib, ibrutinib and zanubrutinib","volume":"35","author":"Estupi\u00f1\u00e1n","year":"2021","journal-title":"Leukemia"},{"key":"B109","doi-asserted-by":"publisher","first-page":"39218","DOI":"10.18632\/oncotarget.16836","article-title":"The bruton\u2019s tyrosine kinase inhibitor ibrutinib exerts immunomodulatory effects through regulation of tumor-infiltrating macrophages","volume":"8","author":"Ping","year":"2017","journal-title":"Oncotarget"},{"key":"B110","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11912-018-0708-8","article-title":"Tyrosine kinase inhibitor-induced hypertension","volume":"20","author":"Agarwal","year":"2018","journal-title":"Curr Oncol Rep"},{"key":"B111","first-page":"215","article-title":"Cardiotoxicity of 5-fluorouracil and capecitabine in a pancreatic cancer patient with a novel mutation in the dihydropyrimidine dehydrogenase gene","volume":"10","author":"Shahrokni","year":"2009","journal-title":"JOP"},{"key":"B112","doi-asserted-by":"publisher","first-page":"e17712","DOI":"10.7759\/cureus.17712","article-title":"Abnormal dihydropyrimidine dehydrogenase activity as an indicator of potential 5-fluorouracil linked cardiotoxicity in colorectal cancer patients: are toxic events inevitable?","volume":"13","author":"Ngassa","year":"2021","journal-title":"Cureus"},{"key":"B113","doi-asserted-by":"publisher","first-page":"e783","DOI":"10.7759\/cureus.783","article-title":"The first case of severe takotsubo cardiomyopathy associated with 5-fluorouracil in a patient with abnormalities of both dihydropyrimidine dehydrogenase (DPYD) and thymidylate synthase (TYMS) genes","volume":"8","author":"Saif","year":"2016","journal-title":"Cureus"},{"key":"B114","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.jaccao.2020.04.005","article-title":"Uridine triacetate for severe fluoropyrimidine cardiotoxicity in a patient with thymidylate synthase gene variants","volume":"2","author":"Raber","year":"2020","journal-title":"Cardio Oncol"},{"key":"B115","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s00432-007-0250-9","article-title":"Cardiotoxicity of fluoropyrimidines in different schedules of administration: a prospective study","volume":"134","author":"Kosmas","year":"2008","journal-title":"J Cancer Res Clin Oncol"},{"key":"B116","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1200\/JCO.1992.10.11.1795","article-title":"Cardiotoxicity of high-dose continuous infusion fluorouracil: a prospective clinical study","volume":"10","author":"De Forni","year":"1992","journal-title":"J Clin Oncol"},{"key":"B117","doi-asserted-by":"publisher","first-page":"e5162","DOI":"10.7759\/cureus.5162","article-title":"Fluorouracil (5-FU)-induced cardiomyopathy","volume":"11","author":"Thalambedu","year":"2019","journal-title":"Cureus"},{"key":"B118","doi-asserted-by":"publisher","first-page":"bcr2015209347","DOI":"10.1136\/bcr-2015-209347","article-title":"5-fluorouracil cardiotoxicity: reversible left ventricular systolic dysfunction with early detection","volume":"2015","author":"Iskandar","year":"2015","journal-title":"Case Reports"},{"key":"B119","doi-asserted-by":"publisher","first-page":"281","DOI":"10.2459\/JCM.0b013e32832e934b","article-title":"5-fluorouracil-induced coronary vasospasm","volume":"11","author":"Bathina","year":"2010","journal-title":"J Cardiovasc Med"},{"key":"B120","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/S0828-282X(06)70905-9","article-title":"Acute coronary syndrome induced by oral capecitabine","volume":"22","author":"Cardinale","year":"2006","journal-title":"Can J Cardiol"},{"key":"B121","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1093\/annonc\/mdh150","article-title":"5-fluorouracil induces arterial vasocontractions","volume":"15","author":"S\u00fcdhoff","year":"2004","journal-title":"Ann Oncol"},{"key":"B122","first-page":"3028","article-title":"In vitro evidence that myocardial ischemia resulting from 5-fluorouracil chemotherapy is due to protein kinase C-mediated vasoconstriction of vascular smooth muscle","volume":"53","author":"Mosseri","year":"1993","journal-title":"Cancer Res"},{"key":"B123","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1177\/107327480401100107","article-title":"5-fluorouracil\u2013induced coronary vasospasm","volume":"11","author":"Shoemaker","year":"2004","journal-title":"Cancer Control"},{"key":"B124","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/BF03086265","article-title":"Capecitabine-induced cardiotoxicity mimicking myocardial infarction","volume":"17","author":"\u015eent\u00fcrk","year":"2009","journal-title":"Neth Heart J"},{"key":"B125","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1002\/1097-0142(19900215)65:4%3C885::AID-CNCR2820650410%3E3.0.CO;2-H","article-title":"Thrombogenicity of intravenous 5-fluorouracil alone or in combination with cisplatin","volume":"65","author":"Kuzel","year":"1990","journal-title":"Cancer"},{"key":"B126","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1021\/ci0501746","article-title":"Effects of 5-fluorouracil on erythrocytes in relation to its cardiotoxicity: membrane structure and functioning","volume":"45","author":"Spasojevi\u0107","year":"2005","journal-title":"J Chem Inf Model"},{"key":"B127","doi-asserted-by":"publisher","first-page":"475","DOI":"10.2165\/00003495-199957040-00003","article-title":"Cardiotoxicity of the antiprolif erative compound fluorouracil","volume":"57","author":"Becker","year":"1999","journal-title":"Drugs"},{"key":"B128","doi-asserted-by":"publisher","first-page":"153113","DOI":"10.1016\/j.tox.2022.153113","article-title":"ROS and iron homeostasis dependent ferroptosis play a vital role in 5-fluorouracil induced cardiotoxicity in vitro and in vivo","volume":"468","author":"Li","year":"2022","journal-title":"Toxicology"},{"key":"B129","doi-asserted-by":"publisher","first-page":"e0115686","DOI":"10.1371\/journal.pone.0115686","article-title":"Effects of 5-fluorouracil on morphology, cell cycle, proliferation, apoptosis, autophagy and ROS production in endothelial cells and cardiomyocytes","volume":"10","author":"Focaccetti","year":"2015","journal-title":"PloS one"},{"key":"B130","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1001\/archneur.1970.00480260061008","article-title":"Biochemical basis for fluorouracil neurotoxicity: the role of krebs cycle inhibition by fluoroacetate","volume":"23","author":"Koenig","year":"1970","journal-title":"Arch Neurol"},{"key":"B131","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1097\/00000421-199910000-00009","article-title":"Severe cardiotoxicity during 5-fluorouracil chemotherapy: a case and literature report","volume":"22","author":"Kuropkat","year":"1999","journal-title":"Am J Clin Oncol"},{"key":"B132","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1016\/j.jacc.2006.09.053","article-title":"Vascular endothelial growth factors: biology and current status of clinical applications in cardiovascular medicine","volume":"49","author":"Yl\u00e4-Herttuala","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"B133","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1016\/S0140-6736(06)69446-4","article-title":"Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial","volume":"368","author":"Demetri","year":"2006","journal-title":"Lancet"},{"key":"B134","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1080\/02841860802314720","article-title":"Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: systematic review and meta-analysis","volume":"48","author":"Zhu","year":"2009","journal-title":"Acta Oncol (Madr)"},{"key":"B135","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1067\/mnc.2001.114148","article-title":"The endothelium: dysfunction and beyond","volume":"8","author":"Herrmann","year":"2001","journal-title":"J Nucl Cardiol"},{"key":"B136","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1161\/HYPERTENSIONAHA.111.173559","article-title":"The vascular endothelial growth factor receptor inhibitor sunitinib causes a preeclampsia-like syndrome with activation of the endothelin system","volume":"58","author":"Kappers","year":"2011","journal-title":"Hypertension"},{"key":"B137","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1126\/science.1104819","article-title":"Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy","volume":"307","author":"Jain","year":"2005","journal-title":"Science"},{"key":"B138","doi-asserted-by":"publisher","first-page":"5780","DOI":"10.1073\/pnas.091415198","article-title":"A cardiac myocyte vascular endothelial growth factor paracrine pathway is required to maintain cardiac function","volume":"98","author":"Giordano","year":"2001","journal-title":"Proc Natl Acad Sci USA"},{"key":"B139","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/nrm1911","article-title":"VEGF receptor signalling? In control of vascular function","volume":"7","author":"Olsson","year":"2006","journal-title":"Nat Rev Mol Cell Biol"},{"key":"B140","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1056\/NEJMoa0707330","article-title":"VEGF inhibition and renal thrombotic microangiopathy","volume":"358","author":"Eremina","year":"2008","journal-title":"New England Journal of Medicine"},{"key":"B141","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1093\/ndt\/gfu368","article-title":"Inhibition of the VEGF signalling pathway and glomerular disorders","volume":"30","author":"Ollero","year":"2015","journal-title":"Nephrol Dial Transplant"},{"key":"B142","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1172\/JCI17189","article-title":"Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia","volume":"111","author":"Maynard","year":"2003","journal-title":"J Clin Invest"},{"key":"B143","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1016\/j.jacc.2015.07.025","article-title":"Vascular and metabolic implications of novel targeted cancer therapies: focus on kinase inhibitors","volume":"66","author":"Li","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"B144","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1172\/JCI118074","article-title":"Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines","volume":"96","author":"De Caterina","year":"1995","journal-title":"J Clin Invest"},{"key":"B145","doi-asserted-by":"publisher","first-page":"4888","DOI":"10.1073\/pnas.95.9.4888","article-title":"Mechanism of platelet inhibition by nitric oxide: in vivo phosphorylation of thromboxane receptor by cyclic GMP-dependent protein kinase","volume":"95","author":"Wang","year":"1998","journal-title":"Proc Natl Acad Sci USA"},{"key":"B146","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.ijcard.2020.05.077","article-title":"Cardiotoxicity of the BCR-ABL1 tyrosine kinase inhibitors: emphasis on ponatinib","volume":"316","author":"Singh","year":"2020","journal-title":"Int J Cardiol"},{"key":"B147","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/j.jaccao.2022.07.001","article-title":"ROCK and rolling towards predicting BCR-ABL kinase inhibitor-induced vascular toxicity","volume":"4","author":"Upshaw","year":"2022","journal-title":"JACC CardioOncol"},{"key":"B148","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1158\/1535-7163.MCT-11-0450","article-title":"Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models","volume":"11","author":"Gozgit","year":"2012","journal-title":"Mol Cancer Ther"},{"key":"B149","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1038\/leu.2013.69","article-title":"Rates of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phase treated with imatinib, nilotinib, or non-tyrosine kinase therapy: a retrospective cohort analysis","volume":"27","author":"Giles","year":"2013","journal-title":"Leukemia"},{"key":"B150","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1038\/s41375-018-0337-0","article-title":". nilotinib-induced metabolic dysfunction: insights from a translational study using in vitro adipocyte models and patient cohorts","volume":"33","author":"Sadiq","year":"2019","journal-title":"Leukemia"},{"key":"B151","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.leukres.2010.11.001","article-title":"Preclinical evaluation of potential nilotinib cardiotoxicity","volume":"35","author":"Wolf","year":"2011","journal-title":"Leuk Res"},{"key":"B152","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.jaccao.2021.01.009","article-title":"Oncotherapeutic protein kinase inhibitors associated with pro-arrhythmic liability","volume":"3","author":"Ye","year":"2021","journal-title":"Cardio Oncology"},{"key":"B153","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1111\/j.1365-2141.2008.07108.x","article-title":"Pleural effusions in patients with chronic myeloid leukaemia treated with dasatinib may have an immune-mediated pathogenesis","volume":"141","author":"De Lavallade","year":"2008","journal-title":"Br J Haematol"},{"key":"B154","doi-asserted-by":"publisher","first-page":"2128","DOI":"10.1161\/CIRCULATIONAHA.111.079921","article-title":"Pulmonary arterial hypertension in patients treated by dasatinib","volume":"125","author":"Montani","year":"2012","journal-title":"Circulation"},{"key":"B155","doi-asserted-by":"publisher","first-page":"3207","DOI":"10.1172\/JCI86249","article-title":"Dasatinib induces lung vascular toxicity and predisposes to pulmonary hypertension","volume":"126","author":"Guignabert","year":"2016","journal-title":"J Clin Invest"},{"key":"B156","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1126\/science.1099480","article-title":"Overriding imatinib resistance with a novel ABL kinase inhibitor","volume":"305","author":"Shah","year":"2004","journal-title":"Science"},{"key":"B157","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1056\/NEJMoa1306494","article-title":"A phase 2 trial of ponatinib in Philadelphia chromosome\u2013positive leukemias","volume":"369","author":"Cortes","year":"2013","journal-title":"N Engl J Med"},{"key":"B158","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1182\/bloodadvances.2019000268","article-title":"Side-effects profile and outcomes of ponatinib in the treatment of chronic myeloid leukemia","volume":"4","author":"Chan","year":"2020","journal-title":"Blood Adv"},{"key":"B159","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1093\/cvr\/cvz006","article-title":"Ponatinib-induced cardiotoxicity: delineating the signalling mechanisms and potential rescue strategies","volume":"115","author":"Singh","year":"2019","journal-title":"Cardiovasc Res"},{"key":"B160","doi-asserted-by":"publisher","first-page":"820","DOI":"10.3390\/jcm9030820","article-title":"Ponatinib induces vascular toxicity through the notch-1 signaling pathway","volume":"9","author":"Madonna","year":"2020","journal-title":"J Clin Med"},{"key":"B161","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1182\/blood-2018-10-881557","article-title":"Thrombotic microangiopathy as a cause of cardiovascular toxicity from the BCR-ABL1 tyrosine kinase inhibitor ponatinib","volume":"133","author":"Latifi","year":"2019","journal-title":"Blood"},{"key":"B162","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21551","article-title":"Cancer statistics, 2019","volume":"69","author":"Siegel","year":"2019","journal-title":"CA Cancer J Clin"},{"key":"B163","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1097\/CRD.0000000000000183","article-title":"Cardiovascular complications of proteasome inhibitors used in multiple myeloma","volume":"26","author":"Cole","year":"2018","journal-title":"Cardiol Rev"},{"key":"B164","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11912-020-0871-6","article-title":"Proteasome inhibitor-related cardiotoxicity: mechanisms, diagnosis, and management","volume":"22","author":"Wu","year":"2020","journal-title":"Curr Oncol Rep"},{"key":"B165","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1056\/NEJMoa1411321","article-title":"Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma","volume":"372","author":"Stewart","year":"2015","journal-title":"N Engl J Med"},{"key":"B166","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.3324\/haematol.2013.089334","article-title":"Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies","volume":"98","author":"Siegel","year":"2013","journal-title":"Haematologica"},{"key":"B167","doi-asserted-by":"publisher","first-page":"134","DOI":"10.37616\/2212-5043.1311","article-title":"Carfilzomib-induced cardiotoxicity: an analysis of the FDA adverse event reporting system (FAERS)","volume":"34","author":"Buck","year":"2022","journal-title":"J Saudi Heart Assoc"},{"key":"B168","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.cardfail.2014.11.008","article-title":"Patterns of cardiac toxicity associated with irreversible proteasome inhibition in the treatment of multiple myeloma","volume":"21","author":"Grandin","year":"2015","journal-title":"J Card Fail"},{"key":"B169","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1182\/blood-2018-06-858415","article-title":"Molecular mechanisms of carfilzomib-induced cardiotoxicity in mice and the emerging cardioprotective role of metformin","volume":"133","author":"Efentakis","year":"2019","journal-title":"Blood"},{"key":"B170","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1038\/nm1574","article-title":"The role of autophagy in cardiomyocytes in the basal state and in response to hemodynamic stress","volume":"13","author":"Nakai","year":"2007","journal-title":"Nat Med"},{"key":"B171","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1161\/01.CIR.0000013839.41224.1C","article-title":"Modulation of anthracycline-induced myofibrillar disarray in rat ventricular myocytes by neuregulin-1\u03b2 and anti-erbB2: potential mechanism for trastuzumab-induced cardiotoxicity","volume":"105","author":"Sawyer","year":"2002","journal-title":"Circulation"},{"key":"B172","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1038\/s41375-021-01141-4","article-title":"Carfilzomib-induced endothelial dysfunction, recovery of proteasome activity, and prediction of cardiovascular complications: a prospective study","volume":"35","author":"Kastritis","year":"2021","journal-title":"Leukemia"},{"key":"B173","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.ebiom.2017.05.024","article-title":"Spasmogenic effects of the proteasome inhibitor carfilzomib on coronary resistance, vascular tone and reactivity","volume":"21","author":"Chen-Scarabelli","year":"2017","journal-title":"EBioMedicine"},{"key":"B174","doi-asserted-by":"publisher","first-page":"e123","DOI":"10.1016\/j.bbmt.2018.12.756","article-title":"Cytokine release syndrome with chimeric antigen receptor T cell therapy","volume":"25","author":"Frey","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"B175","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.1093\/eurheartj\/ehac106","article-title":"Cardiotoxicity from chimeric antigen receptor-T cell therapy for advanced malignancies","volume":"43","author":"Totzeck","year":"2022","journal-title":"Eur Heart J"},{"key":"B176","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1016\/j.jacc.2021.08.044","article-title":"Adverse cardiovascular and pulmonary events associated with chimeric antigen receptor T-cell therapy","volume":"78","author":"Goldman","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"B177","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1038\/s41591-018-0041-7","article-title":"CAR T cell\u2013induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade","volume":"24","author":"Giavridis","year":"2018","journal-title":"Nat Med"},{"key":"B178","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1038\/s41569-020-00492-2","article-title":"Pathophysiology of sepsis-induced cardiomyopathy","volume":"18","author":"Hollenberg","year":"2021","journal-title":"Nat Rev Cardiol"},{"key":"B179","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1182\/blood-2017-08-802413","article-title":"Cytokine release syndrome associated with chimeric-antigen receptor T-cell therapy: clinicopathological insights","volume":"130","author":"Obstfeld","year":"2017","journal-title":"Blood"},{"key":"B180","doi-asserted-by":"publisher","first-page":"3099","DOI":"10.1016\/j.jacc.2019.10.038","article-title":"Cardiovascular events among adults treated with chimeric antigen receptor T-cells (CAR-T)","volume":"74","author":"Alvi","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"B181","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/j.jaccao.2022.09.004","article-title":"Immune checkpoint inhibitor therapy in oncology: current uses and future directions: JACC: cardiooncology state-of-the-art review","volume":"4","author":"Tan","year":"2022","journal-title":"Cardio Oncology"},{"key":"B182","doi-asserted-by":"publisher","first-page":"e192535","DOI":"10.1001\/jamanetworkopen.2019.2535","article-title":"Estimation of the percentage of US patients with cancer who are eligible for and respond to checkpoint inhibitor immunotherapy drugs","volume":"2","author":"Haslam","year":"2019","journal-title":"JAMA Netw Open"},{"key":"B183","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1056\/NEJMoa2109970","article-title":"Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma","volume":"386","author":"Tawbi","year":"2022","journal-title":"N Engl J Med"},{"key":"B184","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1016\/j.jacc.2018.02.037","article-title":"Myocarditis in patients treated with immune checkpoint inhibitors","volume":"71","author":"Mahmood","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"B185","doi-asserted-by":"publisher","first-page":"e013757","DOI":"10.1161\/JAHA.119.013757","article-title":"Immune checkpoint inhibitor myocarditis: pathophysiological characteristics, diagnosis, and treatment","volume":"9","author":"Palaskas","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"B186","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","article-title":"Fulminant myocarditis with combination immune checkpoint blockade","volume":"375","author":"Johnson","year":"2016","journal-title":"N Engl J Med"},{"key":"B187","doi-asserted-by":"publisher","first-page":"4458","DOI":"10.1093\/eurheartj\/ehac456","article-title":"Cardiovascular complications of immune checkpoint inhibitors for cancer","volume":"43","author":"Thuny","year":"2022","journal-title":"Eur Heart J"},{"key":"B188","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1126\/science.291.5502.319","article-title":"Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice","volume":"291","author":"Nishimura","year":"2001","journal-title":"Science"},{"key":"B189","doi-asserted-by":"publisher","first-page":"4735","DOI":"10.1158\/1078-0432.CCR-18-4083","article-title":"Myocarditis in cynomolgus monkeys following treatment with immune checkpoint inhibitors","volume":"25","author":"Ji","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B190","doi-asserted-by":"publisher","first-page":"2299","DOI":"10.1161\/CIRCULATIONAHA.120.049981","article-title":"Association between immune checkpoint inhibitors with cardiovascular events and atherosclerotic plaque","volume":"142","author":"Drobni","year":"2020","journal-title":"Circulation"},{"key":"B191","doi-asserted-by":"publisher","first-page":"107148","DOI":"10.1016\/j.carpath.2019.107148","article-title":"Immune checkpoint inhibition alters the inflammatory cell composition of human coronary artery atherosclerosis","volume":"43","author":"Newman","year":"2019","journal-title":"Cardiovasc Pathol"},{"key":"B192","doi-asserted-by":"publisher","first-page":"e002771","DOI":"10.1136\/jitc-2021-002771","article-title":"Pericardial disease in patients treated with immune checkpoint inhibitors","volume":"9","author":"Gong","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B193","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.jaccao.2021.02.005","article-title":"Takotsubo cardiomyopathy associated with checkpoint inhibitor therapy: endomyocardial biopsy provides pathological insights to dual diseases","volume":"3","author":"Serzan","year":"2021","journal-title":"Cardio Oncol"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2023.1150569\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,8]],"date-time":"2023-09-08T13:48:27Z","timestamp":1694180907000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2023.1150569\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,8]]},"references-count":193,"alternative-id":["10.3389\/fcvm.2023.1150569"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2023.1150569","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,8]]},"article-number":"1150569"}}